EWTX Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small mole…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says Edgewise Therapeutics (EWTX) could benefit from EDG-7500's differentiated drug profile, a potentiall | ||
Biotech Options Buzz: UTHR, NMRA, EWTX UTHR, NMRA, and EWTX are drawing attention from options bears | ||
 Edgewise Therapeutics (EWTX) Trades At A Rich P B, Is The Premium Justified? How Edgewise Therapeutics Stock Has Been Trading Recently Edgewise Therapeutics (EWTX) has drawn investor attention after a period of mixed short term trading, with the stock down 2.4% over the past day but higher over the past month and past 3 months. Shares last closed at US$38.81, with the company’s total return up about 63% year to date and a much larger gain over the past year. These figures prompt closer scrutiny of what is currently priced into the stock. See our latest analysis for... | ||
 Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock? VKTX's Q2 report could hinge on VK2735 pipeline updates as investors await progress on obesity studies and maintenance dosing plans. | ||